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 Figure 1: Areas with distinguishable respiratory motion (white) on the 
patient surface (a). After calibration, motion derived from the body 
surface highly correlates with the Amsterdam Shroud (b) 
 
 PROFFERED PAPERS: CLINICAL 1: PROSTATE CANCER  
  
OC-0048   
Long term results of the Dutch trial for localized prostate cancer: 
Impact on biochemical, clinical and local control 
J. Lebesque1, W. Heemsbergen1, A. Slot2, M. Dielwart3, W. van 
Putten4, A. Al-Mamgani5 
1The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 
Radiation Oncology, Amsterdam, The Netherlands  
2Radiotherapeutic Institute Friesland, Radiation Oncology, 
Leeuwarden, The Netherlands  
3Zeeuws Radiotherapeutic Institute, Radiation Oncology, Vlissingen, 
The Netherlands  
4Erasmus Medical Centre-Daniel den Hoed Cancer Center, Statistical 
Department, Rotterdam, The Netherlands  
5Erasmus Medical Centre-Daniel den Hoed Cancer Center, Radiation 
Oncology, Rotterdam, The Netherlands  
 
Purpose/Objective: We studied the effect of a higher dose on tumor 
control for localized prostate cancer in a randomized trial with a 
median follow-up of 110 months. 
Materials and Methods: Patients with T1b-T4 prostate cancer were 
included in the period 1997-2003 (n=664) and randomized between 78 
Gy (n=333) and 68 Gy (n=331). Primary endpoint was biochemical 
and/or clinical failure (BCF) according the guidelines of the American 
Society for Therapeutic Radiology and Oncology (ASTRO) (3 
consecutive rises). Secondary endpoints were BCF using the Phoenix 
guidelines (nadir plus 2 µg/L), clinical failure (CF), local failure (LF), 
prostate cancer related death (PCRD), and overall survival (OS). 
Explorative subgroup analyses were performed. 
Results: Estimated freedom from BCF at 10 years according ASTRO 
was 45.9 % and 38.4 % for 78 Gy and 68 Gy, respectively (Log Rank, 
p=0.025). Freedom from BCF according Phoenix definition (Table) was 
superior in the 78 Gy arm as well (p=0.046). CF and OS were similar in 
both arms (Table). LF as a first event was significantly less observed in 
the 78 Gy arm (14 versus 27 events, p=0.036, Figure). For progression 
outside the prostate, i.e. documented regional or distant failure, we 
found more first events in the 78 Gy arm, which was not significant 
(59 versus 43 events, p=0.14). At the current update, 205 patients 
were deceased (104 in the 78 Gy arm), including 88 patients with 
PCRD (44 cases in both arms). Subgroup analysis for BCF showed a 
greater benefit for patients with PSA ≥ 10 ug/L compared to <10 ug/L 
(p<0.01 for heterogeneity). Within the subgroup PSA ≥ 10 ug/L, 
estimated freedom from BCF at 10 years (ASTRO) was 41.7 % for the 
78 Gy arm and 30.0 % for the 68 Gy arm (p=0.008). For the subgroup 
PSA < 10 ug/L, these numbers were 54.4 % and 52.6 %, respectively 
(p=0.9). 
 
 
Figure. Kaplan Meier for local failure as a first event (p=0.036) 
 
  
Conclusions: For the first time, a significant difference in LF is 
demonstrated in a randomized trial. However, despite significant 
differences in BCF and LF, no significant differences in CF and OS 
were observed after a median follow-up of 110 months. More follow-
up is needed to identify possible effects for these endpoints. Probably 
only subgroups of the trial population truly benefit from a higher local 
dose in terms of prolonged OS.  
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Purpose/Objective: Bone metastases from renal cell carcinoma (RCC) 
are common and often less responsive to palliative radiotherapy (RT) 
than metastases from other tumors. Sorafenib is a multi-targeted 
tyrosine-kinase inhibitor that improves progression-free survival in 
metastatic RCC. There is pre-clinical evidence to indicate that 
sorafenib also improves the effectiveness of RT. The purpose of this 
study was to examine the efficacy and toxicity of sorafenib in patients 
with RCC receiving palliative RT for painful bone metastases. 
Materials and Methods: Twelve patients with RCC and bone 
metastases were accrued to a phase I/II prospective study of RT and 
sorafenib. An index lesion was identified in each patient and treated 
to a dose of 30 Gy in 10 daily fractions. Sorafenib 200 mg or 400 mg 
per day was administered beginning one week before RT until at least 
nine weeks after RT. Patients who responded to sorafenib were 
eligible to continue beyond 12 weeks. Pain scores were evaluated 
using the Brief Pain Inventory (BPI). 18F-FDG PET imaging was 
performed at baseline (prior to any treatment) and four weeks after 
treatment to assess metabolic response. Standardized uptake values 
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(SUV) were compared using linear-mixed modeling at baseline and at 
four weeks after RT for target and non-target lesions. 
Results: Eleven patients were eligible for analysis. There were 13 
target lesions (two irradiated target lesions in two patients) and 12 
non-target lesions (treated with sorafenib alone). Two patients 
experienced severe toxicity: one developed hand-foot syndrome and 
another died during treatment from unrelated causes. There were no 
severe side effects directly attributable to the combination of RT and 
sorafenib. The BPI mean ‘present’ pain scores at baseline, 7 weeks 
and 12 weeks were 3.9, 1.6, and 1.6 respectively (p = 0.07 for 7 weeks 
vs. baseline; p = 0.13 for 12 weeks versus baseline). There was a 
significant difference in the metabolic response of target lesions 
versus non-target lesions (p=0.002). For target lesions, SUV decreased 
after RT and sorafenib (p=0.003). However, for non-target lesions, 
there was a trend towards an increase in SUV (p=0.09). Only two 
patients required re-irradiation of a previously treated index lesion. 
Seven other patients required subsequent RT for symptomatic 
progression of previously untreated lesions. 
Conclusions: The combination RT and sorafenib is feasible and well 
tolerated as a treatment for palliation of painful bone metastases in 
patients with metastatic RCC. Both the re-treatment and PET results 
suggest that RT provides additional palliative benefit in this patient 
population and should be considered even in those receiving tyrosine-
kinase inhibitors like sorafenib. 
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Purpose/Objective: End point of the present study is to evaluate the 
technical feasibility and early side effects of a short course 
hypofractionated high dose LINAC based SBRT delivered with 
Flattened Filter Free (FFF) beams, and SpaceOAR as a spacer between 
rectum and prostate. 
Materials and Methods: This is a prospective phase-I-II pilot feasibility 
study, started on February 2012. Inclusion criteria were: age ≤ 80 
years, WHO PS ≤ 2, PSA ≤ 20 ng/ml, histologically proven prostate 
adenocarcinoma(risk of microscopic nodal involvement ≤ 15%), T1-T2 
stage, no distant metastases, no previous prostate surgery other than 
TURP, no malignant tumours in the previous 5 years, IPSS 0-7. The 
schedule was 5 x 7 Gy = 35 Gy, delivered in 5 alternative days (NTD2 
between 70 and 85 Gy for an α/β between 3 and 1.5 Gy, respectively). 
SBRT was delivered using the volumetric modulated arc technique by 
RapidArc, with photon beam energy of 10 MV FFF (Filter Flattening 
Free) and maximum dose rate of 2400 MU/min. Physical examinations 
and toxicity assessments were performed during and after SBRT 
according to CTCAE v4.0 toxicity scale. EPIC questionnaires were used 
for Quality of Life assessing. Tumour response was evaluated on 
ASTRO PHOENIX definition (+2 from Nadir of PSA). Neo-
adjuvant/concomitant hormonal therapy was prescribed based on the 
risk according to NCCN classification. SpaceOAR was implanted by 
intraperineal injection as a spacer to enlarge the minimum distance 
between prostate and anterior rectal wall. The SpaceOAR implant was 
optional and based on clinician decision for each case. 
Results: With a median follow-up of 6 months(1-9),40 patients were 
treated with this schedule and were evaluable for the current 
analysis. 34/40 patients were officially recruited in the protocol and 
met perfectly all inclusion criteria. Other 6/40 'out of trial' were 
treated with the same protocol. In the trial, according to NCCN 
criteria, 21/34 patients were low-risk and 12/34 were Intermediate 
risk. Median Age was 69.6(56-80), median initial PSA was 6.33 
ng/ml(range:0.50-12 ng/ml). Median Gleason score was 6.33(6-7). 
Median treatment duration was 11.8 days(9-22). All patients 
completed the treatment as programmed. Acute Toxicities were as 
follow: Rectum G0 in 21/34 cases(62%), G1 in 11/34(33%); G2 in 
2/34(5%). Genito-urinary G0 in 15/34 cases(45%), G1 in 7/34(20%), G2 
in 12/34(35%). In two G2 urinary retention cases, the placement of 
intermittent catheter was needed(in both cases prostate dimension 
was superior than100cc). No acute G3-5 was found in the trial and 'out 
of trial'patients. Median treatment time was 109 seconds(63-124). 
SpaceOAR was implanted in 9 patients with a single case of rectal 
fascia infection resolved with antibiotics. During Follow-up, PSA 
reduction was documented in all treated patients. 
Conclusions: Our early findings suggest that LINAC based SBRT FFF 
treatment for prostate cancer in 5 fractions is feasible, fast and well 
tolerated in acute setting for the first 40 treated patients. Longer 
follow-up is needed for definitive assessment of late toxicity and 
clinical outcome.  
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Purpose/Objective: To assess urinary (GU) function and toxicity in 
patients treated with image-guided proton therapy (PT) for early- and 
intermediate-risk prostate cancer and to analyze the impact of 
pretreatment urinary obstructive symptoms on urinary function after 
PT. 
Materials and Methods: Two prospective trials accrued 171 prostate 
cancer patients from August 2006 to September 2007. Low-risk 
patients received 78 cobalt gray equivalent (CGE) in 39 fractions and 
intermediate-risk patients received 78 to 82 CGE. Median follow-up 
was 5 years. The International Prostate Symptom Score (IPSS) and GU 
toxicities (per CTCAE v3.0 and v4.0) were documented prospectively. 
Results: Five transient GU events were scored Gr 3 per CTCAE v4.0, 
for a cumulative late GU toxicity rate of 2.9% at 5 years. There were 
no Gr 4 or 5 events. On multivariate analysis (MVA), the only factor 
predictive of Gr 2+ GU toxicity was pretreatment GU symptom 
management (p=0.0058).  
Patients with pretreatment IPSS of 15-25 had a decline (clinical 
improvement) in median IPSS from 18 before treatment to 10 at their 
60-month follow-up. At last follow-up,18 (54.5%) patients had a > 5-
point decline, 14 (42.5%) remained stable, and 2 patients (3%) had a > 
5-point rise (deterioration) in IPSS. Patients with IPSS <15 had a stable 
median IPSS of 6 before treatment and at 60 months.  
Conclusions: Urologic toxicity at 5 years with image-guided PT has 
been uncommon and transient. Patients with pretreatment IPSS of < 
15 had stable urinary function 5 years after PT, but patients with 15-
25 showed substantial improvement (decline) in median IPSS, a finding 
not explained by initiation or dose adjustment of alpha blockers. This 
suggests that PT provides a minimally toxic and effective treatment 
for low and intermediate prostate cancer patients, including those 
with significant pretreatment GU dysfunction (IPSS15-25).  
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Purpose/Objective: Accumulating evidence demonstrates the 
sensitivity of prostate cancer to fractionation, estimating a low α/ß 
ratio. This suggests a significant therapeutic benefit of 
hypofractionation, delivering a higher biological dose to the prostate 
without increasing toxicity. To test this hypothesis a randomized 
multicenter phase III Hypofractionation Trial was performed in The 
Netherland. Here we report on the first results of late toxicity. 
Materials and Methods: Between April 2007 and January 2011, 820 
men with localized prostate cancer were included. They were 
randomly assigned to a standard fractionation (SF) arm of 39x2 Gy (5 
fractions a week), or a hypofractionated (HF) arm of 19x3.4 Gy (3 
fractions a week). Primary endpoints were relapse-free survival (RFS) 
and toxicity scores. The late toxicity scores were measured twice a 
year after finishing the radiation course (RC) using RTOG/EORTC 
criteria. The highest grade scored in the follow-up was considered. 
Analyses were done based on the intention to treat. 
Results: To each fractionation arm 410 patients were randomly 
assigned. The median follow-up was 27 months (range 2.3-57 months). 
A grade ≥ 2 late gastrointestinal toxicity (GI) after finishing the RC 
was reported by 15% of the patients treated with SF and by 20% of the 
